e-Therapeutics: Good progress as first commercial deal sought
e-Therapeutics is a pioneer in the field of network-driven drug discovery, NDD, using big data advanced network analytics and machine learning to identify compounds capable of significantly disrupting disease relevant biological networks. Just as big pharma is looking at in silico solutions to address the ongoing R&D productivity issues, e-Therapeutics is demonstrating the utility of its platform in areas of current interest. This fuels our confidence that the company will sign one or more drug discovery alliances in the coming year. To be conservative, our DCF valuation is unchanged at £53.8m or 20.4p/share.
E-Therapeutics is a drug discovery company with a proprietary in silico discovery platform based on the application of network science to the modelling and analysis of cellular processes and utilizing public and proprietary chemical biology and multi-omics data. The therapeutic focus of Co.'s discovery activity is in areas of disease with unmet medical need, including immuno-oncology.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.